YU17899A - Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu - Google Patents

Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu

Info

Publication number
YU17899A
YU17899A YU17899A YU17899A YU17899A YU 17899 A YU17899 A YU 17899A YU 17899 A YU17899 A YU 17899A YU 17899 A YU17899 A YU 17899A YU 17899 A YU17899 A YU 17899A
Authority
YU
Yugoslavia
Prior art keywords
valproic acid
oral administration
pharmaceutical microspheres
microspheres
pharmaceutical
Prior art date
Application number
YU17899A
Other languages
English (en)
Inventor
Christian Langlois
Jean-Yves Lanne
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of YU17899A publication Critical patent/YU17899A/sh
Publication of RS49602B publication Critical patent/RS49602B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na farmaceutske mikrosfere koje sadrže kao aktivnu materiju mešavinu valproinske kiseline i jedne od njenih farmaceutski prihvatljivih soli, zajedno sa matričnom podlogom biranom od glicerinskih estara, hidrogenovanih ulja, esterifikovanih polietilen glikola, voskova i njihovih mešavina.
YUP-178/99A 1996-10-07 1997-10-03 Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu RS49602B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612201A FR2754177B1 (fr) 1996-10-07 1996-10-07 Microspheres pharmaceutiques d'acide valproique pour administration orale

Publications (2)

Publication Number Publication Date
YU17899A true YU17899A (sh) 2000-03-21
RS49602B RS49602B (sr) 2007-06-04

Family

ID=9496427

Country Status (40)

Country Link
US (3) US20020001598A1 (sh)
EP (1) EP0956010B1 (sh)
JP (1) JP3523270B2 (sh)
KR (1) KR100334687B1 (sh)
CN (1) CN100367945C (sh)
AR (1) AR013613A1 (sh)
AT (1) ATE216228T1 (sh)
AU (1) AU731235B2 (sh)
BR (1) BR9712268A (sh)
CA (1) CA2267096C (sh)
CO (1) CO4900080A1 (sh)
CZ (1) CZ288876B6 (sh)
DE (1) DE69712100T2 (sh)
DK (1) DK0956010T3 (sh)
DZ (1) DZ2316A1 (sh)
EE (1) EE03744B1 (sh)
EG (1) EG24070A (sh)
ES (1) ES2174293T3 (sh)
FR (1) FR2754177B1 (sh)
HK (1) HK1021939A1 (sh)
HR (1) HRP970537B1 (sh)
HU (1) HU225103B1 (sh)
ID (1) ID24596A (sh)
IL (1) IL128745A (sh)
IS (1) IS1985B (sh)
ME (1) ME00664B (sh)
MY (1) MY120521A (sh)
NO (1) NO325723B1 (sh)
NZ (1) NZ334399A (sh)
PL (1) PL190105B1 (sh)
PT (1) PT956010E (sh)
RS (1) RS49602B (sh)
RU (1) RU2177315C2 (sh)
SI (1) SI0956010T1 (sh)
SK (1) SK282113B6 (sh)
TR (1) TR199900789T2 (sh)
TW (1) TW508251B (sh)
UY (1) UY24738A1 (sh)
WO (1) WO1998015268A1 (sh)
ZA (1) ZA978954B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775995B2 (en) * 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
CA2508855A1 (en) * 2002-12-16 2004-07-01 Frank Slade Abbott Valproic acid analogues and pharmaceutical compositions thereof
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
MX2007002682A (es) * 2004-09-07 2008-03-05 Orphan Medical Inc Composiciones mejoradas de gamma-hidroxibutirato ghb.
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
CN101543631B (zh) * 2008-03-28 2012-01-11 沈阳兴齐制药有限公司 含蜂蜡的微球基质、含有它的药物组合物及其用途
AU2010248292B2 (en) * 2009-05-12 2014-06-12 Amorepacific Corporation Composition for preventing hair loss or for stimulating hair growth
EA201600387A1 (ru) * 2013-11-13 2016-08-31 Тиллоттс Фарма АГ Дисперсная система доставки лекарственного вещества
CN104013596A (zh) * 2014-05-16 2014-09-03 安士制药（中山）有限公司 一种丙戊酸软胶囊及其制备方法
CN105456217A (zh) * 2014-08-27 2016-04-06 捷思英达医药技术（上海）有限公司 一种双丙戊酸钠缓释剂组合物及其制备方法
JPWO2019039346A1 (ja) 2017-08-24 2020-03-26 三井化学株式会社 電池用非水電解液及びリチウム二次電池
CN111033865A (zh) 2017-08-24 2020-04-17 三井化学株式会社 锂二次电池及非水电解液
FR3087445B1 (fr) * 2018-10-19 2021-12-17 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition lipidique pour l'encapsulation d'une substance active et permettant le controle de la vitesse de liberation de ladite substance active
CN111012753A (zh) * 2020-01-07 2020-04-17 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法
CN112274499A (zh) * 2020-11-16 2021-01-29 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2293974A1 (fr) * 1973-03-02 1976-07-09 Kaltenbach Roger Procede et dispositif pour la granulation reguliere de divers produits
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
TW209174B (sh) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
ATE120089T1 (de) * 1991-05-20 1995-04-15 Marion Laboratories Inc Mehrschichtige zubereitung mit kontrollierter freisetzung.
FR2682677A1 (fr) * 1991-10-17 1993-04-23 Sanofi Elf Complexe forme de l'acide propyl-2 pentene-2 ouique (e) et de son sel de sodium, sa preparation et compositions pharmaceutiques le contenant.
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5690959A (en) * 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
CZ288876B6 (cs) 2001-09-12
HUP9903855A2 (hu) 2000-05-28
HK1021939A1 (en) 2000-07-21
TW508251B (en) 2002-11-01
JP3523270B2 (ja) 2004-04-26
SK36499A3 (en) 2000-12-11
HRP970537A2 (en) 1998-08-31
US20060263437A1 (en) 2006-11-23
US20030157177A1 (en) 2003-08-21
PT956010E (pt) 2002-08-30
DE69712100D1 (de) 2002-05-23
PL332249A1 (en) 1999-08-30
NO325723B1 (no) 2008-07-07
AU731235B2 (en) 2001-03-29
US20020001598A1 (en) 2002-01-03
FR2754177A1 (fr) 1998-04-10
EP0956010B1 (fr) 2002-04-17
SK282113B6 (sk) 2001-11-06
AU4560297A (en) 1998-05-05
HU225103B1 (en) 2006-06-28
US8535721B2 (en) 2013-09-17
BR9712268A (pt) 1999-08-31
ME00664B (me) 2007-06-04
IL128745A0 (en) 2000-01-31
CA2267096C (fr) 2003-09-16
RU2177315C2 (ru) 2001-12-27
EP0956010A1 (fr) 1999-11-17
SI0956010T1 (en) 2002-10-31
NO991613L (no) 1999-04-06
ID24596A (id) 2000-07-27
DE69712100T2 (de) 2002-11-28
WO1998015268A1 (fr) 1998-04-16
HRP970537B1 (en) 2002-08-31
IL128745A (en) 2004-05-12
TR199900789T2 (xx) 1999-07-21
EG24070A (en) 2008-05-11
ZA978954B (en) 1999-04-07
ATE216228T1 (de) 2002-05-15
DK0956010T3 (da) 2002-08-12
RS49602B (sr) 2007-06-04
HUP9903855A3 (en) 2000-06-28
JP2000504038A (ja) 2000-04-04
CO4900080A1 (es) 2000-03-27
CN1232391A (zh) 1999-10-20
PL190105B1 (pl) 2005-10-31
DZ2316A1 (fr) 2002-12-28
IS4996A (is) 1999-03-11
CZ121199A3 (cs) 1999-08-11
CA2267096A1 (fr) 1998-04-16
NO991613D0 (no) 1999-04-06
IS1985B (is) 2005-02-15
KR20000048828A (ko) 2000-07-25
KR100334687B1 (ko) 2002-04-27
UY24738A1 (es) 2001-05-31
EE9900140A (et) 1999-12-15
EE03744B1 (et) 2002-06-17
CN100367945C (zh) 2008-02-13
FR2754177B1 (fr) 1999-08-06
MY120521A (en) 2005-11-30
NZ334399A (en) 2000-05-26
AR013613A1 (es) 2001-01-10
ES2174293T3 (es) 2002-11-01

Similar Documents

Publication Publication Date Title
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ATE307569T1 (de) Gelierbare pharmazeutische zusammensetzungen
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
DK1341527T3 (da) Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix
ES2062543T3 (es) Formulaciones farmaceuticas.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
UA74339C2 (uk) Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
AR002759A1 (es) Composiciones farmaceuticas en dosis unitarias, que incluyen inhibidores de proteinasa.
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
ES2171743T3 (es) Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2172172T3 (es) Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion.
AR012639A1 (es) Estradieno de anillo b, su uso para la manufactura de un medicamento y composicion farmaceutica que lo contiene.
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.
ES2168351T3 (es) Preparaciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion.